SBIR Topic 255: Clinical Translation of Anti-PECAM-1 Monoclonal Antibody as an

SBIR 主题 255：抗 PECAM-1 单克隆抗体作为治疗药物的临床转化

• 批准号: 8164224
• 负责人: ROBERT DEBS
• 金额: $ 19.88万
• 依托单位: GENOMIC SYSTEMS, LLC
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-30 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8164224
• 关键词: Antibodies; CD31 Antigens; Cachexia; Cancer Patient; Clinical; Disseminated Malignant Neoplasm; Dose; Drug Kinetics; Enzyme-Linked Immunosorbent Assay; Frequencies; Goals; Half-Life; Human; Intravenous; Knowledge; Malignant Neoplasms; Marketing; Monoclonal Antibodies; Mus; Neoplasm Metastasis; Patients; Phase; Phase I Clinical Trials; Refractory; Risk; Schedule; Serum; Small Business Innovation Research Grant; Staging; Toxic effect; Translating; Translations; base; design; malignant breast neoplasm; melanoma; pre-clinical; preclinical study; response; tumor

Most patients who die from cancer succumb to advanced metastatic cancer. These patients, are mostoften treatment-refractory, and comprise the largest untapped market in cancer. We have developed a uniquely effective anti-PECAM-1 monoclonal antibody (mAb)-based therapy. To our knowledge, this mAb is the only treatment that safely and effectively treats advanced tumor metastases, independent of tumor type. Clinical translation of anti-PECAM-1 mAb therapy could revolutionize the treatment of this now-refractory clinical entity. Therefore, we propose to perform the following pre-clinical studies required to translate antiPECAM- 1 mAb-based therapy into phase I clinical trials in cancer patients.

大多数死于癌症的患者死于晚期转移性癌症。这些患者通常是治疗难治的，构成了最大的尚未开发的癌症市场。我们已经开发出一种独特有效的基于单抗的抗PECAM-1治疗方法。据我们所知，这种单抗是唯一安全有效地治疗晚期肿瘤转移的治疗方法，不受肿瘤类型的影响。抗PECAM-1单抗治疗的临床翻译可能会彻底改变这种现在难以治愈的临床实体的治疗方法。因此，我们建议进行以下临床前研究，以将基于抗PECAM-1单抗的治疗转化为癌症患者的I期临床试验。